

EMA/651401/2010

European Medicines Agency decision

P/196/2010

of 26 October 2010

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for riociguat (EMA-000718-PIP01-09) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/196/2010

of 26 October 2010

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for riociguat (EMA-000718-PIP01-09) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by Bayer Schering Pharma on 12 November 2009 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 10 September 2010, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.
- (4) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for riociguat, film-coated tablet, oral liquid, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for riociguat, film-coated tablet, oral liquid, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for riociguat, film-coated tablet, oral liquid, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Bayer Schering Pharma, Müllerst. 178, 13342 – Berlin, Germany.

Done at London, 26 October 2010

For the European Medicines Agency
Thomas Lönngren
Executive Director
(Signature on file)

EMA/651401/2010

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMA-000718-PIP01-09

Scope of the application

Active substance(s):

Riociguat

Condition(s):

Treatment of pulmonary hypertension

Pharmaceutical form(s):

Film-coated tablet

Oral liquid

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Bayer Schering Pharma

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Bayer Schering Pharma submitted for agreement to the European Medicines Agency on 12 November 2009 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 23 December 2009.

Supplementary information was provided by the applicant on 25 June 2010.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 18 of said Regulation,
- to grant a deferral in accordance with Article 21 of said Regulation .
- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex(es) and appendix.

London, 10 September 2010

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

1.1. Condition(s):

Treatment of pulmonary hypertension

The waiver applies to:

- the paediatric population from birth to less than 6 years of age
- for film-coated tablet, oral use
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2. Paediatric Investigation Plan

2.1. Condition:

Treatment of pulmonary hypertension

2.1.1. Indication(s) targeted by the PIP

Treatment of primary pulmonary arterial hypertension (PAH)

Treatment of persistent pulmonary hypertension of the Newborn (PPHN)

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Film-coated tablet

Oral liquid

2.1.4. Studies

Area	Number of studies	Description
Quality	1	Study 1: Development of an oral liquid age appropriate formulation.
Non-clinical	2	Study 2: 2-week repeat-dose toxicity study in juvenile rats. Study 3: 13-week repeat-dose toxicity study in juvenile rats.

Clinical	4	Study 4: Physiologically based pharmacokinetic (PBPK) modelling study to predict the pharmacokinetic properties of riociguat in the paediatric population Study 5: Open-label, randomised, single dose, study to assess pharmacokinetics and investigate the relative bioavailability and food effect of the oral liquid formulation of riociguat in healthy adults. Study 6: Open-label, randomised, multicentre, multiple dose study to evaluate safety, tolerability, pharmacokinetics and efficacy of riociguat in children from 28 days to less than 18 years of age with pulmonary arterial hypertension (PAH). Study 7: Open-label, uncontrolled, multicentre study to evaluate pharmacokinetics and efficacy of riociguat as add-on to inhaled nitric oxide (iNO) in neonates with persistent pulmonary hypertension of the newborn (PPHN).
----------	---	---

3. Follow-up, completion and deferral of PIP

Measures to address long term follow-up of potential safety issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By December 2017
Deferral for one or more studies contained in the paediatric investigation plan:	Yes